<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">Inflammatory bowel diseases</z:e> (IBDs), mainly <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> and <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo>, are dynamic, <z:hpo ids='HP_0011010'>chronic</z:hpo> inflammatory conditions that are associated with an increased <z:hpo ids='HP_0003003'>colon cancer</z:hpo> risk </plain></SENT>
<SENT sid="1" pm="."><plain>Inflammatory cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> is a key mechanism for regulating IBD </plain></SENT>
<SENT sid="2" pm="."><plain>Peptidylarginine deiminases (PADs) catalyze the posttranslational conversion of peptidylarginine to peptidylcitrulline in a calcium-dependent, irreversible reaction and mediate the effects of proinflammatory cytokines </plain></SENT>
<SENT sid="3" pm="."><plain>Because PAD levels are elevated in mouse and human <z:hpo ids='HP_0002583'>colitis</z:hpo>, we hypothesized that a novel small-molecule inhibitor of the PADs, i.e., chloramidine (Cl-<z:chebi fb="0" ids="2634">amidine</z:chebi>), could suppress <z:hpo ids='HP_0002583'>colitis</z:hpo> in a <z:chebi fb="0" ids="34674">dextran sulfate</z:chebi> <z:chebi fb="199" ids="26708">sodium</z:chebi> mouse model </plain></SENT>
<SENT sid="4" pm="."><plain>Results are consistent with this hypothesis, as demonstrated by the finding that Cl-<z:chebi fb="0" ids="2634">amidine</z:chebi> treatment, both prophylactic and after the <z:hpo ids='HP_0003674'>onset</z:hpo> of disease, reduced the clinical signs and symptoms of <z:hpo ids='HP_0002583'>colitis</z:hpo>, without any indication of toxic side effects </plain></SENT>
<SENT sid="5" pm="."><plain>Interestingly, Cl-<z:chebi fb="0" ids="2634">amidine</z:chebi> drives <z:mpath ids='MPATH_3'>apoptosis</z:mpath> of inflammatory cells in vitro and in vivo, providing a mechanism by which Cl-<z:chebi fb="0" ids="2634">amidine</z:chebi> suppresses <z:hpo ids='HP_0002583'>colitis</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>In total, these data help validate the PADs as therapeutic targets for the treatment of IBD and further suggest Cl-<z:chebi fb="0" ids="2634">amidine</z:chebi> as a candidate therapy for this disease </plain></SENT>
</text></document>